Cyclerion Therapeutics - CYCN Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cyclerion Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CYCN shares.
View CYCN analyst ratings or view top-rated stocks.

2 brokerages have issued 12 month price targets for Cyclerion Therapeutics' stock. Their CYCN share price forecasts range from $7.00 to $14.00. On average, they expect the company's stock price to reach $10.50 in the next year. This suggests a possible upside of 1,021.3% from the stock's current price.
View analysts price targets for CYCN or view top-rated stocks among Wall Street analysts.

Cyclerion Therapeutics' stock was trading at $1.72 at the beginning of the year. Since then, CYCN stock has decreased by 45.6% and is now trading at $0.9364.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our CYCN earnings forecast.

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) announced its earnings results on Tuesday, November, 9th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.09. The company had revenue of $0.35 million for the quarter, compared to the consensus estimate of $3 million. Cyclerion Therapeutics had a negative trailing twelve-month return on equity of 115.98% and a negative net margin of 2,551.69%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclerion Therapeutics investors own include Fulcrum Therapeutics (FULC), Ovid Therapeutics (OVID), Spectrum Pharmaceuticals (SPPI), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Xeris Biopharma (XERS), Abeona Therapeutics (ABEO), ACADIA Pharmaceuticals (ACAD), Aimmune Therapeutics (AIMT) and Celldex Therapeutics (CLDX).

Cyclerion Therapeutics trades on the NASDAQ under the ticker symbol "CYCN."

Cyclerion Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (5.84%), Franklin Resources Inc. (0.18%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Andreas Busch, Mark G Currie, Peter M Hecht, Peter M Hecht, Slate Path Capital Lp, Terrance Mcguire and William Huyett.
View institutional ownership trends.

Shares of CYCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CYCN stock can currently be purchased for approximately $0.94.

Cyclerion Therapeutics (NASDAQ:CYCN) has a market capitalization of $40.69 million and generates $3.94 million in revenue each year. The company earns $-51,650,000.00 in net income (profit) each year or ($1.11) on an earnings per share basis.

Cyclerion Therapeutics' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for the company is www.cyclerion.com. The company can be reached via phone at (857) 327-8778 or via email at ir@cyclerion.com.